×
New Modalities for Genomic Profiling of HER2+ Breast Cancer
https://www.practiceupdate.com/content/new-modalities-for-genomic-profiling-of-her2-breast-cancer-from-sabcs-2017/61675/62

Dec 8th, 2017 - New Modalities for Genomic Profiling of HER2+ Breast Cancer From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

ER positive breast cancer: Screening for clinical variables to predict late distance disease recurrence
https://ecancer.org/conference/966-sabcs-2017/video/6562/er-positive-breast-cancer--screening-for-clinical-variables-to-predict-late-distance-disease-recurrence.php

Dec 9th, 2017 - Dr Ivana Sestak speaks with ecancer at SABCS 2017 about screening for clinical variables to predict late distance disease recurrence among women with ER positive breast cancer following endocrine therapy.

CDK 4/6 inhibitors for older women with HR-positive breast cancer
https://ecancer.org/conference/966-sabcs-2017/video/6573/cdk-4-6-inhibitors-for-older-women-with-hr-positive-breast-cancer.php

Dec 9th, 2017 - Harpreet Singh speaks at a SABCS 2017 press session about how older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6).

Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients
https://ecancer.org/conference/966-sabcs-2017/video/6576/circulating-tumour-cells-may-predict-late-recurrence-in-hr-positive-breast-cancer-patients.php

Dec 9th, 2017 - Dr Joseph Sparano speaks at a SABCS 2017 press session about how his findings show that a single positive CTC assay result five years after diagnosis provides independent prognostic information for late recurrence.

New Data on the Second Line Treatment of HER2+ Breast Cancer
https://www.practiceupdate.com/content/new-data-on-the-second-line-treatment-of-her2-breast-cancer-from-sabcs-2017/61715/62

Dec 11th, 2017 - New Data on the Second Line Treatment of HER2+ Breast Cancer From SABCS 2017 Interview with Jame Abraham MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA

Postmenopausal women who lose weight may have reduced breast cancer risk
https://ecancer.org/conference/966-sabcs-2017/video/6575/postmenopausal-women-who-lose-weight-may-have-reduced-breast-cancer-risk.php

Dec 9th, 2017 - Prof Rowan Chlebowski speaks at a SABCS 2017 press session about how postmenopausal women who lose weight may have reduced breast cancer risk.

Rowan T. Chlebowski, MD, PhD, on Weight Loss and Breast Cancer Risk: Results From the Women’s Health Initiative
http://www.ascopost.com/videos/2017-san-antonio-breast-cancer-symposium/rowan-t-chlebowski-md-phd-on-weight-loss-and-breast-cancer-risk-results-from-the-women-s-health-initiative/

Dec 7th, 2017 - Rowan T. Chlebowski, MD, PhD, of the City of Hope National Medical Center, discusses 11-year followup results that showed a significantly lower breast cancer incidence among women with a greater than 5% weight loss (Abstract GS5-07).

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial
http://www.ascopost.com/videos/2017-san-antonio-breast-cancer-symposium/sherene-loi-md-phd-and-roberto-salgado-md-phd-on-her2plus-metastatic-breast-cancer-results-from-the-panaceakeynote-014-trial/

Dec 8th, 2017 - Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients with trastuzumab-resistant disease (Abstract GS2-06).

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer
https://ecancer.org/conference/966-sabcs-2017/video/6532/adjuvant-trastuzumab-did-not-improve-outcomes-for-patients-with-her2-low-breast-cancer.php

Dec 7th, 2017 - Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.

HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival
https://ecancer.org/conference/966-sabcs-2017/video/6533/her2low-invasive-breast-cancer--trastuzumab-offers-no-improvement-for-invasive-disease-free-survival.php

Dec 7th, 2017 - Dr Fehrenbacher speaks with ecancer at SABCS 2017 about a phase III trial of adjuvant chemotherapy with or without trastuzumab for HER2low invasive breast cancer.

Wolfgang Janni, MD, PhD, on Early Breast Cancer and Bisphosphonate Treatment: Results From the SUCCESS A Trial
http://www.ascopost.com/videos/2017-san-antonio-breast-cancer-symposium/wolfgang-janni-md-phd-on-early-breast-cancer-and-bisphosphonate-treatment-results-from-the-success-a-trial/

Dec 6th, 2017 - Wolfgang Janni, MD, PhD, of Ulm University, discusses study findings that showed extended adjuvant bisphosphonate treatment over 5 years in early breast cancer does not improve disease-free and overall survival when compared with 2 years of treatment (Abstract GS1-06).

The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone
https://ecancer.org/conference/966-sabcs-2017/video/6534/the-soft-trial--comparing-adjuvant-tamoxifen-with-ovarian-function-suppression-via-exemestane-to-tamoxifen-alone.php

Dec 8th, 2017 - Dr Gini Fleming speaks with ecancer at SABCS 2017 about the outcomes of the SOFT trial comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone.

Management of Locoregional Recurrence in Breast Cancer
http://www.cancernetwork.com/sabcs-street-team/management-locoregional-recurrence-breast-cancer

Dec 14th, 2017 - William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, reviews the management of locoregional recurrence in breast cancer.

Breast cancer therapy resistance mediated by FGFR amplification
https://ecancer.org/conference/966-sabcs-2017/video/6569/breast-cancer-therapy-resistance-mediated-by-fgfr-amplification.php

Dec 9th, 2017 - Dr Luigi Formisano speaks with ecancer at SABCS 2017 about breast cancer therapy resistance mediated by FGFR amplification.

Updates on the Management of Male Breast Cancer
http://www.cancernetwork.com/sabcs-street-team/updates-management-male-breast-cancer

Dec 12th, 2017 - N. Lynn Henry, MD, PhD, of the University of Utah Huntsman Cancer Institute, highlights four abstracts investigating the use of hereditary gene panels and methods to predict prognosis in male breast cancer.

The role of axiliary node dissection in modern breast cancer surgery
https://ecancer.org/conference/966-sabcs-2017/video/6564/the-role-of-axiliary-node-dissection-in-modern-breast-cancer-surgery.php

Dec 9th, 2017 - Dr Viviana Galimberti speaks with ecancer at SABCS 2017 about the role of axillary node dissection in modern breast cancer surgery.

Preserving Fertility in Breast Cancer Patients After Chemotherapy
http://www.cancernetwork.com/sabcs-street-team/preserving-fertility-breast-cancer-patients-after-chemotherapy

Dec 12th, 2017 - Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic in Rochester, Minnesota, discusses four abstracts on preserving fertility in premenopausal breast cancer patients treated with chemotherapy

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
http://www.medscape.com/viewarticle/890560

Dec 9th, 2017 - Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.

Precision Imaging in Breast Cancer
http://www.cancernetwork.com/sabcs-street-team/precision-imaging-breast-cancer

Dec 12th, 2017 - Maxine S. Jochelson, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses four posters on the use of mammography, magnetic resonance imaging (MRI), and radiomics as biomarkers for treatment response

Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy
https://ecancer.org/conference/966-sabcs-2017/video/6563/anastrozole-duration-for-post-menopausal-breast-cancer-patients-after-5-years-of-endocrine-therapy.php

Dec 9th, 2017 - Prof Michael Gnant speaks with ecancer at SABCS 2017 to discuss the outcomes of a multi-centre phase III randomised trial of 2 or 5 years of anastrozole for post-menopausal breast cancer patients after 5 years of endocrine therapy.